• A
  • A
Font Size
EYLEA patient assistance program

For patients who lack insurance coverage for EYLEA or are uninsured, the Patient Assistance Program (PAP) provideseligible patients with EYLEA free of charge. To qualify, you must:

  • Be uninsured or lack insurance coverage for EYLEA
  • Live in the United States or its territories or possessions
  • Show financial need (based on total annual household adjusted gross income*)

*You will need to provide financial documentation to support this information.

If I qualify for the Patient Assistance Program, what happens once I'm enrolled?

Once EYLEA4U® receives your application, your Support Specialist will:

Verify that you meet the program requirements.

Send a confirmation letter about your enrollment to your doctor's office upon approval.

Make sure that your EYLEA gets shipped to your doctor's office.


We've got you covered

When your eye doctor prescribes EYLEA, whether you have private or government insurance (Medicare/Medicaid) or have no insurance coverage, you can be confident that EYLEA4U is here to help. And we can conduct a Benefits Investigation with your insurer to determine your coverage for EYLEA.


Support Specialists

Your live link to EYLEA4U

EYLEA4U Support Specialists are your link to the EYLEA4U support programs. They will listen to your story, answer your questions, and help determine what support program may work for you.

Right from the start, EYLEA4U Support Specialists are ready to help by:

  • Providing information about your health plan
  • Finding the support program that's best for you
  • Working with your doctor's office and health plan to help determine your coverage

Getting support

When we say "we're here for you," we stand behind it—online and by phone at 1-855-EYLEA4U (1-855-395-3248) 9 AM to 8 PM Eastern Time (press 2 for Medical Information questions, 3 to report an adverse event, 4 for patient assistance programs, and 6 if you need help getting to and from your eye appointments).

Download the Financial Assistance Brochure

Important Safety Information
  • EYLEA® (aflibercept) Injection is a prescription medication administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.
Top
Important Safety Information
  • EYLEA® (aflibercept) Injection is a prescription medication administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.
  • Injection into the eye with EYLEA can result in an infection in the eye and retinal detachment (separation of retina from back of the eye). Inflammation in the eye has been reported with the use of EYLEA.
  • In some patients, injections with EYLEA may cause a temporary increase in eye pressure within 1 hour of the injection. Sustained increases in eye pressure have been reported with repeated injections, and your doctor may monitor this after each injection.
  • There is a potential risk of serious and sometimes fatal side effects related to blood clots, leading to heart attack or stroke in patients receiving EYLEA.
  • Serious side effects related to the injection procedure with EYLEA are rare but can occur including infection inside the eye and retinal detachment.
  • The most common side effects reported in patients receiving EYLEA are increased redness in the eye, eye pain, cataract, moving spots in the field of vision, increased pressure in the eye, and vitreous (gel-like substance) detachment.
  • It is important that you contact your doctor right away if you think you might be experiencing any side effects, including eye pain or redness, light sensitivity, or blurring of vision, after an injection.
  • EYLEA is for prescription use only. For additional safety information, please talk to your doctor and see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Indications

EYLEA® (aflibercept) Injection is a prescription medicine approved for the treatment of patients with:

  • Wet Age-related Macular Degeneration (AMD): The recommended dose for EYLEA is 2 mg administered by injection in the eye every 2 months (8 weeks) following 3 initial monthly (every 4 weeks) injections. EYLEA may be dosed once per month, but in most patients, additional benefit was not seen with this dosing plan. Some patients may need monthly (every 4 weeks) dosing after the first 3 months (12 weeks).
  • Macular Edema following Retinal Vein Occlusion (RVO): The recommended dose for EYLEA is 2 mg administered by injection in the eye monthly (every 4 weeks).
  • Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR) in patients with DME: The recommended dose for EYLEA is 2 mg administered by injection in the eye every 2 months (8 weeks) following 5 initial monthly (every 4 weeks) injections. EYLEA may be dosed once per month, but in most patients, additional benefit was not seen with this dosing plan. Some patients may need monthly (every 4 weeks) dosing after the first 5 months (20 weeks).
Please see the full Prescribing Information for EYLEA.

The information contained herein is provided for general educational purposes. If you have any questions, talk to your doctor.